Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Short Interest Down 7.3% in May

drop of 35.9% from the April 30th total of 661,500 shares. Based on an average daily volume of 1,490,000 shares, the short-interest ratio is currently 0.3 days. The number of shares shorted has decreased significantly in the past month.

( ) has seen a dramatic drop in short interest during the month of may. On May 15th there were 422,900 shorted shares. This is a 7.3% drop from the 456,300 shares on April 30th. At the moment, 4.8% are shorted. The short-interest rate is currently 5.7, based on an average daily share volume of 74,000.

Hedge Funds weigh in on Chemomab Therapeutics

Several institutional investors recently changed their holdings in CMMB. Kestra Private Wealth Services LLC purchased a $100,000 stake in Chemomab therapeutics during the fourth quarter. Boothbay Fund Management LLC grew its holdings in Chemomab therapeutics shares by 38.1% over the course of the fourth quarter. Boothbay Fund Management LLC owns 51 608 shares worth $165,000, after adding 14,237 more shares during the last quarter. Renaissance Technologies LLC purchased a new share of Chemomab Therapeutics in the first quarter, valued at approximately $134,000. Citadel Advisors LLC purchased a new position in shares of Chemomab Therapeutics during the third quarter, valued at about $53,000. Envestnet Asset Management Inc. purchased a new position of Chemomab Therapeutics during the first quarter, valued at approximately $52,000. Trading was down $0.01 at midday on Wednesday to $1.57. The company traded 5,967 shares compared to an average of 539 296. The 50-day moving average is $1.59, and the 200-day moving average is $1.92. Chemomab Therapeutics's 52-week low is $1.38, and its 52-week high is $5.35. The company's market capitalization is $17.35 million. It has a price to earnings ratio of -0.57, and a beta value of 0.35.

The company last released its earnings on Monday, 20th March. The company posted ($0.72) earnings per share for the third quarter, exceeding analysts' expectations of ($0.80), by $0.08. Analysts predict that Chemomab Therapeutics's EPS will be -1.7 for the year.

Analysts set new price targets

Oppenheimer also lowered its price target on shares of Chemomab Therapeutics in a research report on Tuesday, 18th April, from $12.00 down to $7.00.

Chemomab Therapeutics Company profile

Get Rating

Chemomab Therapeutics Ltd. is a biotech company in the clinical stage that discovers and develops therapeutics to treat inflammation and fibrosis. The company's leading clinical product candidate, CM-101 is a humanized polyclonal antigen that inhibits the basic function soluble chemokine CCL24 in the treatment of primary sclerosing cholangitis and systemic sclerosis. offers a FREE daily email newsletter